- Home
- TRDA
as 07-26-2024 4:00pm EST
Entrada Therapeutics Inc clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Its pipeline includes solutions for Neuromuscular Disease, Beyond Neuromuscular, and Platform Expansion.
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | BOSTON |
| Market Cap: | 577.6M | IPO Year: | 2021 |
| Target Price: | $20.00 | AVG Volume (30 days): | 156.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.64 | EPS Growth: | N/A |
| 52 Week Low/High: | $10.75 - $18.17 | Next Earning Date: | 08-06-2024 |
| Revenue: | $162,873,000 | Revenue Growth: | 544.79% |
| Revenue Growth (this year): | 10.34% | Revenue Growth (next year): | -59.08% |
Stock Insider Trading Activity of Entrada Therapeutics Inc. (TRDA)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Sethuraman Natarajan | TRDA | Chief Scientific Officer | Jul 12 '24 | Sell | $18.00 | 638 | $11,484.00 | 188,814 | SEC Form 4 |
| Sethuraman Natarajan | TRDA | Chief Scientific Officer | Jul 12 '24 | Sell | $18.00 | 600 | $10,800.00 | 189,452 | SEC Form 4 |
| WENTWORTH KORY JAMES | TRDA | Chief Financial Officer | Jul 8 '24 | Sell | $14.95 | 1,758 | $26,282.10 | 81,412 | SEC Form 4 |
| Doshi Dipal | TRDA | CEO | Jun 13 '24 | Sell | $16.17 | 1,000 | $16,173.60 | 336,375 | SEC Form 4 |
| Doshi Dipal | TRDA | CEO | May 16 '24 | Sell | $15.00 | 1,800 | $27,000.00 | 338,575 | SEC Form 4 |
| Doshi Dipal | TRDA | CEO | May 16 '24 | Sell | $15.11 | 1,200 | $18,129.12 | 337,375 | SEC Form 4 |
| Sethuraman Natarajan | TRDA | Chief Scientific Officer | May 16 '24 | Sell | $15.00 | 1,000 | $15,000.00 | 208,032 | SEC Form 4 |
| Sethuraman Natarajan | TRDA | Chief Scientific Officer | May 16 '24 | Sell | $15.14 | 8,305 | $125,750.99 | 199,727 | SEC Form 4 |
| Sethuraman Natarajan | TRDA | Chief Scientific Officer | May 16 '24 | Sell | $15.19 | 9,675 | $146,943.90 | 190,052 | SEC Form 4 |
| KIM PETER S | TRDA | Director | May 14 '24 | Buy | $14.59 | 25,000 | $364,672.50 | 92,412 | SEC Form 4 |
| KIM PETER S | TRDA | Director | May 8 '24 | Buy | $14.04 | 2,276 | $31,964.60 | 65,212 | SEC Form 4 |
| KIM PETER S | TRDA | Director | May 8 '24 | Buy | $14.25 | 2,200 | $31,340.98 | 67,412 | SEC Form 4 |
| KIM PETER S | TRDA | Director | Apr 8 '24 | Buy | $13.57 | 2,600 | $35,289.80 | 62,936 | SEC Form 4 |
| KIM PETER S | TRDA | Director | Mar 28 '24 | Buy | $13.75 | 1,512 | $20,793.93 | 60,336 | SEC Form 4 |
| KIM PETER S | TRDA | Director | Mar 22 '24 | Buy | $13.76 | 3,118 | $42,900.56 | 52,894 | SEC Form 4 |
| KIM PETER S | TRDA | Director | Mar 22 '24 | Buy | $13.36 | 3,180 | $42,472.08 | 56,074 | SEC Form 4 |
| KIM PETER S | TRDA | Director | Mar 22 '24 | Buy | $13.64 | 2,750 | $37,509.17 | 58,824 | SEC Form 4 |
| KIM PETER S | TRDA | Director | Mar 19 '24 | Buy | $12.66 | 900 | $11,396.97 | 47,944 | SEC Form 4 |
| KIM PETER S | TRDA | Director | Mar 19 '24 | Buy | $12.66 | 1,128 | $14,280.93 | 49,072 | SEC Form 4 |
| KIM PETER S | TRDA | Director | Mar 19 '24 | Buy | $13.24 | 704 | $9,317.65 | 49,776 | SEC Form 4 |
| WENTWORTH KORY JAMES | TRDA | Chief Financial Officer | Mar 6 '24 | Sell | $12.31 | 4,086 | $50,285.18 | 74,170 | SEC Form 4 |
| Dowden Nathan J | TRDA | President & COO | Mar 6 '24 | Sell | $12.32 | 1,826 | $22,498.69 | 137,204 | SEC Form 4 |
| Doshi Dipal | TRDA | CEO | Feb 15 '24 | Sell | $15.00 | 1,000 | $15,000.00 | 243,279 | SEC Form 4 |
| Doshi Dipal | TRDA | CEO | Jan 16 '24 | Sell | $15.99 | 1,000 | $15,990.00 | 244,279 | SEC Form 4 |
| WENTWORTH KORY JAMES | TRDA | Chief Financial Officer | Dec 21 '23 | Sell | $15.07 | 2,200 | $33,154.66 | 49,571 | SEC Form 4 |
Latest Entrada Therapeutics Inc. News
TRDA Breaking Stock News: Dive into TRDA Ticker-Specific Updates for Smart Investing
Zacks
a day ago
Wall Street Analysts See a 25.73% Upside in Entrada Therapeutics (TRDA): Can the Stock Really Move This High?
Zacks
14 days ago
Entrada Therapeutics (TRDA) Moves 10.4% Higher: Will This Strength Last?
Zacks
17 days ago
Strength Seen in Travere (TVTX): Can Its 8.8% Jump Turn into More Strength?
Zacks
17 days ago
Best Momentum Stocks to Buy for July 9th
Simply Wall St.
a month ago
With 40% ownership, Entrada Therapeutics, Inc. (NASDAQ:TRDA) has piqued the interest of institutional investors
MT Newswires
a month ago
Entrada Therapeutics Signs Securities Purchase Agreement of 3.4 Million Common Shares in Registered Direct Offering
GlobeNewswire
a month ago
Entrada Therapeutics Announces $100 Million Registered Direct Offering
GlobeNewswire
a month ago
Entrada Therapeutics Reports Positive Preliminary Data in Healthy Volunteers from Phase 1 ENTR-601-44-101 Trial for Duchenne Muscular Dystrophy
Compare TRDA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TRDA Entrada Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.